$7.290
+0.238 (+3.26%)收盘时
SOPH 资讯
SOPH 事件
Sophia Genetics and Myriad Genetics Collaborate to Advance Prostate Cancer Genomic Instability Score Technology
Sophia Genetics (SOPH) and Myriad Genetics (MYGN) announced a collaboration to advance new prostate cancer-specific genomic instability score technology - or PrGIS - to support precision oncology approaches with AstraZeneca (AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency, or HRD, in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, SSophia Genetics is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad's PrGIS technology and aim to expand patient access to PrGIS in global markets.
Myriad Genetics and Sophia Genetics Collaborate to Advance Prostate Cancer Genomic Instability Score Technology
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with AstraZeneca (AZN). PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
Company Expects Adjusted EBITDA Loss Between $29M and $32M
Consensus $93.38M. The company also expects an adjusted EBITDA loss between $29M and $32M.
Company Reports Q2 Revenue of $23.3M, Beating Expectations
Reports Q2 revenue $23.3M, consensus $21.72M. Performance was driven by 60% volume growth in the U.S. and 80% revenue growth in Liquid Biopsy. We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%," said CEO Ross Muken.
Sophia Genetics $40M Spot Secondary Re-offered at $4.75
Sophia Genetics $40M Spot Secondary re-offered at $4.75
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。